CAR T 세포 치료 시장 분석 및 예측 : 유형별, 제품 유형별, 서비스별, 기술별, 용도별, 최종 사용자별, 프로세스별, 단계별, 솔루션별(-2035년)

CAR T Cell Therapy Market is anticipated to expand from $6 billion in 2024 to $21.8 billion by 2034, growing at a CAGR of approximately 13.8%. The CAR T Cell Therapy Market encompasses the development and commercialization of chimeric antigen receptor T-cell therapies, which are engineered to target and destroy cancer cells. This market is characterized by cutting-edge advancements in genetic engineering and personalized medicine. The increasing prevalence of cancer and the demand for innovative treatments are propelling growth, with a focus on improving efficacy, safety, and accessibility. Key trends include collaborations between biotech firms and academic institutions, regulatory advancements, and the expansion of clinical trials globally.

The CAR T Cell Therapy Market is experiencing robust growth, propelled by advancements in immunotherapy and personalized medicine. The segment focusing on hematological malignancies dominates, with therapies targeting B-cell malignancies such as leukemia and lymphoma leading in efficacy and adoption. Solid tumors represent the second highest performing segment, showcasing promising developments in targeting specific antigens. Within the hematological segment, the sub-segment of CD19-targeted therapies is particularly prominent, driven by their success in treating certain leukemias and lymphomas. The sub-segment addressing BCMA-targeted therapies is gaining momentum, reflecting significant strides in combating multiple myeloma. In the solid tumor segment, advancements in targeting antigens like HER2 and EGFR are notable, offering potential breakthroughs. Ongoing research and clinical trials are expanding the therapeutic landscape, underscoring the importance of innovative approaches in overcoming treatment resistance. Investment in manufacturing capabilities and regulatory pathways is crucial to scaling these therapies, ensuring broader access and affordability.

Market Snapshot:

The CAR T Cell Therapy market is witnessing a dynamic shift with significant advancements in market share, pricing strategies, and product launches. The market is characterized by a robust pipeline of innovative therapies and a strategic focus on competitive pricing. Key players are introducing novel treatments, enhancing their portfolios to capture larger market segments. The landscape is further enriched by collaborations and partnerships, fostering a competitive edge and driving growth. In terms of competition, the market is marked by intense rivalry among leading pharmaceutical companies. Benchmarking reveals that companies are leveraging advanced technologies to maintain competitive advantages. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics. These regulations ensure safety and efficacy, influencing market entry and expansion strategies. The market is poised for growth, driven by technological advancements, increasing prevalence of cancer, and rising demand for personalized medicine. Challenges such as high treatment costs and regulatory hurdles persist, yet the potential for innovation remains substantial.

Geographical Overview:

The CAR T Cell Therapy market is witnessing notable expansion across various regions, each demonstrating unique growth dynamics. North America remains at the forefront, propelled by pioneering research and substantial investments in biotechnology. The presence of leading pharmaceutical companies and advanced healthcare infrastructure further bolsters the market. Europe follows, with robust research initiatives and favorable regulatory frameworks fostering innovation in CAR T Cell Therapy. The region's commitment to personalized medicine enhances its market position. In Asia Pacific, the market is burgeoning, driven by increased healthcare spending and technological advancements. Countries like China and Japan are emerging as key players, investing heavily in research and development. Latin America and the Middle East & Africa are increasingly recognizing the potential of CAR T Cell Therapy. In Latin America, growing healthcare awareness and infrastructure improvements are driving market growth. Meanwhile, the Middle East & Africa are focusing on strategic collaborations to enhance their capabilities in this transformative therapy.

Key Trends and Drivers:

The CAR T Cell Therapy Market is experiencing robust growth fueled by advancements in genetic engineering and immunotherapy. Key trends include the development of next-generation CAR T cells, which are designed to enhance specificity and reduce toxicity. Innovations in manufacturing processes are driving down costs, making therapies more accessible to a broader patient base. Furthermore, regulatory support and fast-track approvals are accelerating the introduction of new therapies into the market. The rising prevalence of cancer and hematological malignancies is a significant driver, increasing demand for effective treatment options. Collaborations between biotech companies and research institutions are fostering innovation, leading to the development of novel CAR T cell products. Opportunities are abundant in expanding the therapeutic indications beyond oncology, exploring applications in autoimmune diseases and infectious diseases. The growing investments in research and development are expected to yield transformative therapies, positioning the CAR T Cell Therapy Market for sustained growth and substantial advancements in patient care.

Restraints and Challenges:

The CAR T Cell Therapy Market faces several significant restraints and challenges. A primary challenge is the exorbitant cost associated with CAR T cell therapies, which limits accessibility for many patients. This high cost stems from complex manufacturing processes and personalized treatment regimens. Regulatory hurdles also pose a significant barrier, as therapies must undergo rigorous testing and approval procedures, prolonging time to market. Moreover, the market is constrained by a lack of skilled professionals who can administer and manage these advanced therapies. This shortage impacts the scalability and widespread adoption of CAR T cell treatments. Additionally, there is a risk of severe side effects, including cytokine release syndrome, which can deter patients and healthcare providers. Finally, logistical challenges in the supply chain, such as the need for precise temperature control and timely delivery, complicate the distribution of CAR T cell therapies. These factors collectively impede market growth and accessibility.

Key Players:

Legend Biotech, Autolus Therapeutics, Cellectis, Poseida Therapeutics, Tessa Therapeutics, Adaptimmune Therapeutics, Kite Pharma, Allogene Therapeutics, Caribou Biosciences, Cabaletta Bio, Immatics, Atara Biotherapeutics, Genocea Biosciences, Sorrento Therapeutics, Precision BioSciences

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Stage
• 2.9 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Autologous CAR T Cell Therapy
  • 4.1.2 Allogeneic CAR T Cell Therapy
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Yescarta
  • 4.2.2 Kymriah
  • 4.2.3 Tecartus
  • 4.2.4 Breyanzi
  • 4.2.5 Abecma
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Research and Development
  • 4.3.2 Manufacturing
  • 4.3.3 Quality Control
  • 4.3.4 Regulatory Compliance
  • 4.3.5 Clinical Trials
  • 4.3.6 Logistics
  • 4.3.7 Consulting
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Gene Editing
  • 4.4.2 Lentiviral Vectors
  • 4.4.3 CRISPR
  • 4.4.4 Sleeping Beauty Transposon
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Hematologic Malignancies
  • 4.5.2 Solid Tumors
  • 4.5.3 Non-Hodgkin Lymphoma
  • 4.5.4 Acute Lymphoblastic Leukemia
  • 4.5.5 Multiple Myeloma
  • 4.5.6 Chronic Lymphocytic Leukemia
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Cancer Treatment Centers
  • 4.6.3 Research Institutes
  • 4.6.4 Biotechnology Companies
  • 4.6.5 Pharmaceutical Companies
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Cell Collection
  • 4.7.2 Cell Engineering
  • 4.7.3 Cell Expansion
  • 4.7.4 Quality Testing
  • 4.7.5 Cryopreservation
• 4.8 Market Size & Forecast by Stage (2020-2035)
  • 4.8.1 Preclinical
  • 4.8.2 Clinical Trials
  • 4.8.3 Commercialization
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Patient Monitoring
  • 4.9.2 Data Management
  • 4.9.3 Supply Chain Management

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Process
    • 5.2.1.8 Stage
    • 5.2.1.9 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Process
    • 5.2.2.8 Stage
    • 5.2.2.9 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Process
    • 5.2.3.8 Stage
    • 5.2.3.9 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Process
    • 5.3.1.8 Stage
    • 5.3.1.9 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Process
    • 5.3.2.8 Stage
    • 5.3.2.9 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Process
    • 5.3.3.8 Stage
    • 5.3.3.9 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Process
    • 5.4.1.8 Stage
    • 5.4.1.9 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Process
    • 5.4.2.8 Stage
    • 5.4.2.9 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Process
    • 5.4.3.8 Stage
    • 5.4.3.9 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Process
    • 5.4.4.8 Stage
    • 5.4.4.9 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Process
    • 5.4.5.8 Stage
    • 5.4.5.9 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Process
    • 5.4.6.8 Stage
    • 5.4.6.9 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Process
    • 5.4.7.8 Stage
    • 5.4.7.9 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Process
    • 5.5.1.8 Stage
    • 5.5.1.9 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Process
    • 5.5.2.8 Stage
    • 5.5.2.9 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Process
    • 5.5.3.8 Stage
    • 5.5.3.9 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Process
    • 5.5.4.8 Stage
    • 5.5.4.9 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Process
    • 5.5.5.8 Stage
    • 5.5.5.9 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Process
    • 5.5.6.8 Stage
    • 5.5.6.9 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Process
    • 5.6.1.8 Stage
    • 5.6.1.9 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Process
    • 5.6.2.8 Stage
    • 5.6.2.9 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Process
    • 5.6.3.8 Stage
    • 5.6.3.9 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Process
    • 5.6.4.8 Stage
    • 5.6.4.9 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Process
    • 5.6.5.8 Stage
    • 5.6.5.9 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Legend Biotech
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Autolus Therapeutics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Cellectis
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Poseida Therapeutics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Tessa Therapeutics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Adaptimmune Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Kite Pharma
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Allogene Therapeutics
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Caribou Biosciences
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Cabaletta Bio
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Immatics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Atara Biotherapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Genocea Biosciences
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Sorrento Therapeutics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Precision BioSciences
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us